SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-23-055992
Filing Date
2023-05-04
Accepted
2023-05-04 16:05:41
Documents
60
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q cldx-20230331x10q.htm   iXBRL 10-Q 992412
2 EXHIBIT 31.1 cldx-20230331xex31d1.htm EX-31.1 13783
3 EXHIBIT 31.2 cldx-20230331xex31d2.htm EX-31.2 13788
4 EXHIBIT 32.1 cldx-20230331xex32d1.htm EX-32.1 7344
  Complete submission text file 0001104659-23-055992.txt   4972317

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA cldx-20230331.xsd EX-101.SCH 30737
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cldx-20230331_cal.xml EX-101.CAL 39445
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cldx-20230331_def.xml EX-101.DEF 134843
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20230331_lab.xml EX-101.LAB 326956
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20230331_pre.xml EX-101.PRE 230185
54 EXTRACTED XBRL INSTANCE DOCUMENT cldx-20230331x10q_htm.xml XML 968366
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 23888593
SIC: 2835 In Vitro & In Vivo Diagnostic Substances